Recent Updates
Recently added Catalysts
BNGO Positive Sentiment Score: 75/100

Bionano to Present at the Healthcare Virtual Conference

Key Takeaway: Bionano Genomics, Inc. (BNGO) announced its participation in the Healthcare Virtual Conference hosted by M-Vest and Maxim Group LLC. CEO Erik Holmlin is scheduled to present a company overview and engage in a fire-side chat during the event. The company, known for innovative genome analysis solutions, aims to transform genomic insights through its advanced offerings. Bionano also provides diagnostic services for neurodevelopmental disabilities, enhancing its role in the healthcare sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • Bionano Genomics will participate in a significant Healthcare Virtual Conference.
  • The event features a presentation by the company's CEO, showcasing their advancements.
  • Bionano is recognized for its innovative genome analysis solutions.
  • The company offers industry-leading software and diagnostic services.

Full Press Release Details

SAN DIEGO, June 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced that the company will participate at the Healthcare Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest. Erik Holmlin, Ph.D., Bionano’s president and chief executive officer, is scheduled to present a company overview and fire-side chat discussion hosted by Michael Okunewitch, Senior Research Analyst at Maxim Group on Wednesday, June 21, 2023 at 12:30 pm ET.
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. The Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. For more information, visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
Bionano Genomics, Inc.

Frequently Asked Questions

What conference will Bionano Genomics participate in?

Bionano Genomics will participate in the Healthcare Virtual Conference on June 21, 2023.

Who is presenting for Bionano at the conference?

Erik Holmlin, Ph.D., the CEO, will present at the conference.

What solutions does Bionano provide?

Bionano offers genome analysis solutions for research, diagnostics, and software.

What does Bionano's diagnostic testing focus on?

Their diagnostic testing focuses on autism spectrum disorder and neurodevelopmental disabilities.

What technology does Bionano use for nucleic acid extraction?

Bionano uses proprietary isotachophoresis (ITP) technology for nucleic acid extraction.

Last updated: Jun 21, 2023